Cytochroma to present at the Cowen and Company 32nd Annual Healthcare Conference

MARKHAM, ON, Feb. 29, 2012 /CNW/ - Cytochroma today announced that Dr. Charles W. Bishop, Cytochroma's President and Chief Executive Officer, will present a corporate overview at the Cowen and Company 32^nd Annual Health Care Conference.  This presentation is scheduled at 2:00 PM ET on Monday, March 5, 2012 at the Boston Marriott Copley Place.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD).  The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD.  Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stage development.

Please visit www.cytochroma.com.

Cytochroma Investors:
Gordon Ngan
Executive Director, Corporate Development
Tel: [phone] ext. 333
[email protected]

Cytochroma Media:
Robert Stanislaro (FTI Consulting)
Tel: [phone]
[email protected]